{
    "id": 10000005,
    "name": "Indication other than cancer",
    "source": "JAX",
    "definition": "Indication other than cancer",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": null,
    "altIds": [
        
    ],
    "termId": "JAX:10000005",
    "evidence": [
        {
            "id": 1978,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Gleevec (imatinib) is FDA approved for patients with aggressive systemic mastocytosis in which c-KIT mutational status is unknown (FDA.gov).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000005,
                "name": "Indication other than cancer",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 286,
                    "pubMedId": null,
                    "title": "FDA.gov",
                    "url": "http://www.fda.gov/"
                },
                {
                    "id": 15459,
                    "pubMedId": null,
                    "title": "Gleevec (imatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021588"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1979,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Gleevec (imatinib) is not indicated for patients with aggressive systemic mastocytosis harboring KIT D816V (FDA.gov).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000005,
                "name": "Indication other than cancer",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15459,
                    "pubMedId": null,
                    "title": "Gleevec (imatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021588"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2065,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Ofev (nintedanib) is FDA approved for use in patients with idiopathic pulmonary fibrosis (FDA.gov).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000005,
                "name": "Indication other than cancer",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 286,
                    "pubMedId": null,
                    "title": "FDA.gov",
                    "url": "http://www.fda.gov/"
                },
                {
                    "id": 15591,
                    "pubMedId": null,
                    "title": "Ofev (nintedanib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205832"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2493,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Glucophage (metformin) is FDA approved for use in patients with type-2 diabetes (FDA.gov).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10000005,
                "name": "Indication other than cancer",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 286,
                    "pubMedId": null,
                    "title": "FDA.gov",
                    "url": "http://www.fda.gov/"
                },
                {
                    "id": 15594,
                    "pubMedId": null,
                    "title": "Glucophage (metformin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020357"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2494,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rapamune (sirolimus) is FDA approved for use in patients with lymphangioleiomyomatosis and for prophylactic immunosuppression in renal transplant patients (FDA.gov).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000005,
                "name": "Indication other than cancer",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 286,
                    "pubMedId": null,
                    "title": "FDA.gov",
                    "url": "http://www.fda.gov/"
                },
                {
                    "id": 15599,
                    "pubMedId": null,
                    "title": "Rapamune (sirolimus) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021083"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2826,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PP30 inhibited proliferation of mouse embryonic fibroblasts more effectively than rapamycin (PMID: 19209957).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2241,
                "therapyName": "PP30",
                "synonyms": null
            },
            "indication": {
                "id": 10000005,
                "name": "Indication other than cancer",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2064,
                    "pubMedId": 19209957,
                    "title": "Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19209957"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3616,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Valproic acid is FDA approved for use in patients with seizures, migraines, and bipolar disorder (FDA.gov).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1076,
                "therapyName": "Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 10000005,
                "name": "Indication other than cancer",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 286,
                    "pubMedId": null,
                    "title": "FDA.gov",
                    "url": "http://www.fda.gov/"
                },
                {
                    "id": 15675,
                    "pubMedId": null,
                    "title": "Stavzor (valproic acid) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022152"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4754,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Gilenya (fingolimod) is FDA approved for use in patients with relapsing forms of multiple sclerosis (FDA.gov).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3610,
                "therapyName": "Fingolimod",
                "synonyms": null
            },
            "indication": {
                "id": 10000005,
                "name": "Indication other than cancer",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 286,
                    "pubMedId": null,
                    "title": "FDA.gov",
                    "url": "http://www.fda.gov/"
                },
                {
                    "id": 15609,
                    "pubMedId": null,
                    "title": "Gilenya (fingolimod) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022527"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        
    ]
}